GlassScriptPhysician profile
Cindy Huang
NPI 1356570063
$20,809.66
in general payments reported to CMS, 2019-2025
52 companies · $2,437 in 2025
The $2,437 reported for 2025 was more than what 80% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,042 · 2020: $2,885 · 2021: $2,869 · 2022: $3,255 · 2023: $2,841 · 2024: $2,481 · 2025: $2,437.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,758.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,758.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $3,575.24 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $2,242.31 | 2019-2025 | Mounjaro, Jardiance, Trulicity |
| Astrazeneca Pharmaceuticals LP | $2,163.93 | 2019-2023 | Farxiga |
| Sanofi-Aventis U.S. LLC | $1,284.71 | 2019-2025 | |
| Amgen INC. | $1,209.21 | 2019-2025 | Tepezza, Prolia, Evenity |
| Abbvie INC. | $866.35 | 2020-2025 | |
| Insulet Corporation | $804.58 | 2022-2024 | Omnipod |
| Xeris Pharmaceuticals, INC. | $792.82 | 2020-2025 | Gvoke Hypopen |
| Boehringer Ingelheim Pharmaceuticals, INC. | $771.71 | 2020-2025 | Jardiance |
| Mannkind Corporation | $670.46 | 2019-2025 | Afrezza |
| Bayer Healthcare Pharmaceuticals INC. | $583.18 | 2021-2025 | |
| Glaxosmithkline, LLC. | $529.38 | 2019-2025 | Arexvy, Shingrix, Benlysta |
| Corcept Therapeutics | $519.28 | 2019-2025 | Korlym |
| Amarin Pharma, INC. | $465.99 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $363.93 | 2022-2025 | Strensiq |
Show all 52 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zealand Pharma US, INC. | $351.70 | 2020-2022 | |
| Dexcom, INC. | $320.34 | 2021-2025 | Dexcom G6 Transmitter |
| Pfizer INC. | $305.90 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $249.36 | 2019-2025 | Capvaxive, Gardasil 9 |
| Janssen Biotech, INC. | $172.32 | 2020-2022 | |
| Ibsa Pharma INC. | $171.08 | 2020-2025 | Tirosint, Tirosint, Licart |
| Ascendis Pharma Endocrinology INC | $159.97 | 2025 | Yorvipath |
| Medtronic, INC. | $159.16 | 2021-2024 | Minimed 780g, Accurian, Inpen Smart Insulin Delivery System |
| Mallinckrodt Hospital Products INC. | $158.60 | 2021-2022 | |
| Madrigal Pharmaceuticals | $156.81 | 2024-2025 | Rezdiffra, Resmetirom |
| Radius Health, INC. | $147.97 | 2019-2025 | Tymlos |
| Vistapharm, INC. | $134.92 | 2021 | |
| Horizon Therapeutics Plc | $127.77 | 2021-2023 | Tepezza |
| Amag Pharmaceuticals, INC. | $125.00 | 2019 | |
| Gilead Sciences, INC. | $114.76 | 2019 | |
| Soleno Therapeutics, INC. | $104.35 | 2025 | Vykat Xr |
| Ascensia Diabetes Care US INC. | $102.43 | 2019-2024 | |
| Abbott Laboratories | $101.34 | 2019-2023 | Freestyle Libre 3 |
| Alvogen INC | $98.12 | 2022-2023 | Teriparatide |
| Tandem Diabetes Care, INC. | $90.95 | 2023-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Mallinckrodt Enterprises LLC | $62.15 | 2019 | |
| Beta Bionics, INC. | $60.28 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Takeda Pharmaceuticals U.S.A., INC. | $59.08 | 2020-2021 | |
| Sequel Med Tech, LLC | $58.22 | 2025 | Twiist |
| Becton, Dickinson and Company | $49.65 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $39.80 | 2020-2025 | Cobenfy |
| Amphastar Pharmaceuticals, INC. | $38.06 | 2024-2025 | |
| Exact Sciences Corporation | $35.73 | 2023 | Cologuard Collection Kit |
| Recordati_rare_diseases_inc. | $28.68 | 2024 | Isturisa, Signifor Lar |
| Rhythm Pharmaceuticals, INC. | $27.82 | 2025 | Imcivree |
| Esperion Therapeutics, INC. | $27.40 | 2021 | |
| Fresenius Kabi USA, LLC | $26.60 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $25.50 | 2023 | Nuedexta |
| Boston Scientific Corporation | $22.68 | 2025 | General - Pain Management |
| Kyowa Kirin, INC. | $18.18 | 2023 | |
| Dermira, INC. | $17.13 | 2020 | |
| Theracosbio, LLC | $16.77 | 2024 | Brenzavvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cindy Huang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.